Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New contact lens takes on popular brand in vision showdown

NCT ID NCT07345416

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new daily disposable contact lens called ST-1 against an existing lens, Miru 1day UpSide, in 63 people with nearsightedness. Participants will wear the lenses daily for 3 months and have their vision and eye comfort checked regularly. The goal is to see if the new lens works as well or better for correcting vision and keeping eyes comfortable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ST-1 silicone hydrogel daily disposable soft contact lenses
What this could lead to
If successful, this could show that ST-1 lenses are a safe and effective option for daily myopia correction, offering similar or better comfort and vision than existing lenses.
What could go wrong
This is a small, early-stage study with only 63 participants, so results may not apply to everyone. There is always a risk of discomfort or eye health issues with contact lenses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 63 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. With either gender aged between 18 to 40 (inclusive) years old. 2. Diagnosis of myopia in both eyes, each ranging from -0.50D to 6.00D with manifest astigmatism of ≤ 1.00D per eye. 3. Understands and signs an informed consent form (ICF). 4. Willing to adhere to the instructions set forth in this study as well as understand and complete all specified evaluation. 5. Willing and able to refrain from using any other contact lenses other than those provided for the duration of the study. 6. Has experience and capability of wearing soft contact lenses. 7. Be a habitual soft contact lenses wearer in both eyes, defined as wearing lenses for at least 8 hours per day, 5 days per week, for a minimum duration of 30 days. 8. Tear breakup time (TBUT) \> 5 seconds in each eye. Exclusion Criteria: 1. Eyes with abnormality or disease as follows: 1. Evidence of lid abnormality or infection (e.g., entropion, ectropion, chalazia, and recurrent styes). 2. Clinically significant slit lamp findings (e.g., infiltrates or other slit lamp findings Level 2 or above: corneal edema, tarsal abnormalities, and conjunctival injection). 3. Other active ocular disease (e.g., uveitis, corneal epithelial defect, severe dry eye, lacrimal duct defect, glaucoma, cornea \[infiltrates\], conjunctiva, lids, and intraocular infection or inflammation of an allergic, bacterial, or viral etiology). 4. History of recurrent corneal erosions. 5. Aphakia. 2. Ocular or systemic allergies or diseases that may interfere with contact lens wear, occur within 2 weeks prior to the Screening Visit. 3. Use of topical ocular medications, except artificial tear, within 7 days prior to the Screening Visit. 4. History of refractive, ocular, or intraocular surgery. 5. Participation in any clinical trial (with the exception of retrospectives studies) within 30 days prior to the Screening Visit. 6. Have risks in dangerous and significant eye edema, congestions, corneal abrasion or neovascularization when wearing contact lens. 7. Any corneal surface roughness. 8. Unable to achieve best corrected visual acuity (BCVA) of logMAR 0.1 or better in each eye at distance using manifest refraction. 9. Females who are pregnant, breastfeeding or who intend to become pregnant over the course of the study. 10. Current drug or alcohol use or dependence that, in the opinion of the Investigator, would interfere with adherence to study requirement. 11. Allergy to any component in the study product. 12. Subjects who wore monovision, multifocal, toric, or rigid contact lenses within 30 days prior to the Screening Visit. Note: Monovision is defined as a vision correction method for treating presbyopia in which the dominant eye is corrected for distance vision and the non-dominant eye is corrected for near vision. 13. Use of systemic medications (e.g., chronic steroid use) that are known to interfere with contact lenses wear at the Investigators discretion within 14 days prior to the Screening Visit. 14. Other conditions not suitable for participating in this study judged by the Investigators. 15. Live in dusty or pharmaceutical environments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Daily disposable soft contact lenses are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chang-Gung Memorial Hospital LinKou Branch

    Taoyuan, Taoyuan City, 33305, Taiwan

  • Changhua Christian Hospital

    Changhua, Changhua City, 50006, Taiwan

  • Far Eastern Memorial Hospital

    New Taipei City, New Taipei City, 220, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Kaohsiung City, 80756, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taipei City, 11217, Taiwan

  • Tri-Service General Hospital

    Taipei, Taipei City, 114202, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.